Global, Regional, and National Burden of Alopecia Areata and its Associated Comorbidities, 1990–2021, and Projections to 2050: An Analysis of the Global Burden of Disease Study 2021

Authors

  • Dan Wang Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, P. R. China
  • Peizhi Deng Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, P. R. China
  • Shengbo Yang Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, P. R. China
  • Yangfan Xu Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, P. R. China
  • Jianyun Lu Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, P. R. China; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

DOI:

https://doi.org/10.2340/actadv.v105.43367

Keywords:

Alopecia areata, Epidemiology, GBD 2021, Anxiety disorder, COVID-19, Prediction

Abstract

There are no updated epidemiological data on alopecia areata up to 2021. The objective of this study was to emphasize the urgency of addressing the evolving public health challenges of alopecia areata. The annual point prevalence, incidence, and years lived with disability of alopecia areata from 204 countries and regions from 1990–2021 were extracted. Subgroup analyses based on gender, age, global, national, regional, sociodemographic index, and World Bank income were conducted. From 1990–2021, age-standardized prevalence, incidence, and years lived with disability of alopecia areata globally show a decreasing trend, with females dominating. There was a reduction in the disease burden in high sociodemographic index regions, but alopecia areata in general did not reflect a concentration in certain regions and was more equally distributed. Decomposition analysis revealed that population growth was the major contributor to the burden of alopecia areata, followed by population ageing. Patients with alopecia areata before the age of 14 were associated with anxiety disorders and other psychological disorders, but patients after the age of 14 were not associated with the onset of these disorders. Also, atopic dermatitis has been associated with alopecia areata. The epidemiological differences in psychological disorders between children and adolescents/adults with alopecia areata further demonstrate the importance of differentiated recognition at different ages.

Downloads

Download data is not yet available.

References

Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 1: 1–12. DOI: https://doi.org/10.1016/j.jaad.2017.04.1141

Jang H, Park S, Kim MS, Yon DK, Lee SW, Koyanagi A, et al. Global, regional and national burden of alopecia areata and its associated diseases, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019. Eur J Clin Invest 2023; 6: e13958. DOI: https://doi.org/10.1111/eci.13958

Murray CJL. The Global Burden of Disease study at 30 years. Nat Med 2022; 10: 2019–2026. DOI: https://doi.org/10.1038/s41591-022-01990-1

Harris E. COVID-19 associated with higher risk of autoimmune diseases. JAMA 2024; 15: 1266. DOI: https://doi.org/10.1001/jama.2024.2092

Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol 2020; 1: 123–130. DOI: https://doi.org/10.1016/j.jaad.2020.03.004

Liu Z, Liu Y, Yan L, Li Q. Trends in the global burden of disease for mental disorders among children aged 0–14 years, 1990–2021. J Affect Disord 2025; 119325. DOI: https://doi.org/10.1016/j.jad.2025.04.156

Zheng J, Zhang D, Zhang S, Chen M, Guo Z, Guan S, et al. Global burden of malaria and neglected tropical diseases in children and adolescents, 1990–2019: a population-based, cross-sectional study. J R Soc Med 2025; 3: 82–96. DOI: https://doi.org/10.1177/01410768251321572

Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines – part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004; 3: 440–447. DOI: https://doi.org/10.1016/j.jaad.2003.09.032

Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol 2018; 1: 15–24. DOI: https://doi.org/10.1016/j.jaad.2017.04.1142

Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK Inhibitors for treatment of alopecia areata. J Invest Dermatol 2018; 9: 1911–1916. DOI: https://doi.org/10.1016/j.jid.2018.05.027

Wang H, Pan L, Wu Y. Epidemiological trends in alopecia areata at the global, regional, and national levels. Front Immunol 2022; 874677. DOI: https://doi.org/10.3389/fimmu.2022.874677

Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol 2020; 3: 675–682. DOI: https://doi.org/10.1016/j.jaad.2019.08.032

Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol 2023; 4: 411–418. DOI: https://doi.org/10.1001/jamadermatol.2023.0002

King BA, Craiglow BG. Janus kinase inhibitors for alopecia areata. J Am Acad Dermatol 2023; 2S: S29–S32. DOI: https://doi.org/10.1016/j.jaad.2023.05.049

Murray CJL, GBD 2021 Collaborators. Findings from the Global Burden of Disease Study 2021. Lancet 2024; 10440: 2259–2262. DOI: https://doi.org/10.1016/S0140-6736(24)00769-4

Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 1999; 2 Pt 1: 242–246. DOI: https://doi.org/10.1016/S0190-9622(99)70195-7

Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 16: 1515–1525. DOI: https://doi.org/10.1056/NEJMra1103442

GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 2023; 10: e594–e610.

Wang S, Dong Z, Wan X. Global, regional, and national burden of inflammatory bowel disease and its associated anemia, 1990 to 2019 and predictions to 2050: an analysis of the Global Burden of Disease Study 2019. Autoimmun Rev 2024; 3: 103498. DOI: https://doi.org/10.1016/j.autrev.2023.103498

Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 6: 1284–1293. DOI: https://doi.org/10.1111/all.13401

GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 5: 459–480.

Desai MK, Brinton RD. Autoimmune disease in women: endocrine transition and risk across the lifespan. Front Endocrinol 2019; 265. DOI: https://doi.org/10.3389/fendo.2019.00265

Zhang M, Lin X, Yang Z, Li X, Zhou Z, Love PE, et al. Metabolic regulation of T cell development. Front Immunol 2022; 946119. DOI: https://doi.org/10.3389/fimmu.2022.946119

Kyriakis KP, Paltatzidou K, Kosma E, Sofouri E, Tadros A, Rachioti E. Alopecia areata prevalence by gender and age. J Eur Acad Dermatol Venereol JEADV 2009; 5: 572–573. DOI: https://doi.org/10.1111/j.1468-3083.2008.02956.x

Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet 2021; 10277: 914–927. DOI: https://doi.org/10.1016/S0140-6736(21)00359-7

Wehry AM, Beesdo-Baum K, Hennelly MM, Connolly SD, Strawn JR. Assessment and treatment of anxiety disorders in children and adolescents. Curr Psychiatry Rep 2015; 7: 52. DOI: https://doi.org/10.1007/s11920-015-0591-z

Muntyanu A, Gabrielli S, Donovan J, Gooderham M, Guenther L, Hanna S, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol JEADV 2023 DOI: https://doi.org/10.1111/jdv.18926

Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: a multifactorial autoimmune condition. J Autoimmun 2019; 74–85. DOI: https://doi.org/10.1016/j.jaut.2018.12.001

Downloads

Additional Files

Published

2025-08-18

How to Cite

Wang, D., Deng, P., Yang, S., Xu, Y., & Lu, J. (2025). Global, Regional, and National Burden of Alopecia Areata and its Associated Comorbidities, 1990–2021, and Projections to 2050: An Analysis of the Global Burden of Disease Study 2021. Acta Dermato-Venereologica, 105, adv43367. https://doi.org/10.2340/actadv.v105.43367

Issue

Vol. 105 (2025)

Section

Articles

Categories

License

Copyright (c) 2025 Dan Wang, Peizhi Deng, Shengbo Yang, Yangfan Xu, Jianyun Lu

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC